antibody-drug conjugate
Elevation Oncology Narrows EO-3021 Trial to Claudin 18.2-Expressing Patients, Launches Combo Cohorts
The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.
FDA Grants Priority Review to AstraZeneca, Daiichi Sankyo's Dato-DXd
In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.
AstraZeneca, Daiichi Sankyo Withdraw EU Application for Dato-DXd in Nonsquamous NSCLC
The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.
Alentis Therapeutics Raises $181.4M in Series D Financing
The firm plans to put the funds toward advancing its CLDN-1-directed antibody-drug conjugates, ALE.P02 and ALE.P03, into the clinic.
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Jul 11, 2024
Myricx Bio Raises £90M in Series A Financing
Mar 14, 2024
Tubulis Raises $139M in Series B2 Funding
Oct 25, 2023